menu
    • menu
    [{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Mutabilis","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"2G-Dabocins","moa":"Diazabicyclooctanes penicillin-binding proteins","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Organovo Holdings \/ Novo Holdings","highestDevelopmentStatusID":"2","companyTruncated":"Organovo Holdings \/ Novo Holdings"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Tarveda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Termination","leadProduct":"Locnartecan","moa":"Topoisomerase 1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Organovo Holdings \/ Organovo","highestDevelopmentStatusID":"7","companyTruncated":"Organovo Holdings \/ Organovo"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"FXR314","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Organovo Holdings \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ Not Applicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"FXR314","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Organovo Holdings","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"","sponsorNew":"Organovo Holdings \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Organovo Holdings \/ Not Applicable"},{"orgOrder":0,"company":"Organovo Holdings","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"FXR314","moa":"","graph1":"Gastroenterology","graph2":"Phase I","graph3":"Organovo Holdings","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gastroenterology","amount2New":0.01,"dosageForm":"","sponsorNew":"Organovo Holdings \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"6","companyTruncated":"Organovo Holdings \/ JonesTrading Institutional Services"}]

    Find Clinical Drug Pipeline Developments & Deals by Organovo Holdings

    Menu

    Organovo Holdings

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : JonesTrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering

                            Details : Proceeds will advance the company's pipeline, including lead molecule FXR314, targeting inflammatory bowel disease and applications in metabolic liver disease.

                            Brand Name : FXR314

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 08, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : JonesTrading Institutional Services

                            Deal Size : $5.2 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Organovo Reveals Positive Phase 2 Results for FXR314 in MASH

                            Details : The company’s lead molecule, FXR314, the non-steroidal, non-bile acid FXR agonist, is being developed for the treatment of metabolic function-associated steatohepatitis (MASH).

                            Brand Name : FXR314

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 15, 2024

                            Lead Product(s) : FXR314

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data

                            Details : FXR314, an FXR agonist, has completed initial clinical trials. FXR314 is a drug with safety and tolerability after daily oral dosing in Phase 1 and Phase 2 trials. Further, FXR314 has FDA clinical trial authorization for a Phase 2 trial in ulcerative col...

                            Brand Name : FXR314

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 23, 2023

                            Lead Product(s) : FXR314

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Locnartecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : Tarveda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Tarveda Therapeutics Provides Update on Proposed Merger with Organovo

                            Details : Unanticipated late opposition by major Organovo stockholder results in termination of proposed merger agreement.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            April 07, 2020

                            Lead Product(s) : Locnartecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Tarveda Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Organovo Holdings

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : 2G-Dabocins

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : Mutabilis

                            Deal Size : $11.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Novo Holdings REPAIR Impact Fund Invests USD 12 Million in Mutabilis and IBT Vaccines and Provides Strategic U...

                            Details : This investment will allow the Mutabilis to accelerate its 2G-Dabocins program, a wide spectrum Gram-negative anti-infective agent, which is currently undergoing lead optimization.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 06, 2020

                            Lead Product(s) : 2G-Dabocins

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : Mutabilis

                            Deal Size : $11.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth